A company formed this year in Bangalore by Kiran Mazumdar-Shaw, Kush Parmar and Siddhartha Mukherjee plans to bring a CAR T therapy to cancer patients in India for about $50,000 per treatment. That cost, which includes hospital and medical expenses, would be 20 to 40 times lower than that of CAR T treatments in the U.S.
Right now, CAR T isn’t available at any price in India, and some Indian patients have traveled to the U.S. and paid more than $1 million for the treatment.
Immuneel Therapeutics Private Ltd. hopes to pioneer business and care delivery models that, if successful, could change the way CAR T and other cell therapies are developed and manufactured around the world.
The company’s founders believe they can achieve cost savings and make it far easier to make iterative improvements by redefining CAR T therapies as procedures like stem cell transplants rather than as drugs. This will allow them to establish a decentralized system for manufacturing the therapies at individual hospitals.
While $50,000 is out of reach for most Indians,